$TYRA
Tyra Biosciences, Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022014802 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.730M $3.381M $5.189M
YoY Change 136.57% 200.0% 653.12%
% of Gross Profit
Research & Development $10.92M $12.05M $9.645M
YoY Change 99.03% 174.98% 173.85%
% of Gross Profit
Depreciation & Amortization $82.00M $69.00M $64.00K
YoY Change 100.0% 165.38% 190.91%
% of Gross Profit
Operating Expenses $13.65M $15.43M $14.83M
YoY Change 105.56% 180.1% 252.27%
Operating Profit -$13.65M -$15.43M -$14.83M
YoY Change 105.56% 180.1% 252.27%
Interest Expense $1.131M $346.0K $18.00K
YoY Change 56450.0% 11433.33% 800.0%
% of Operating Profit
Other Income/Expense, Net $1.136M $333.0K $8.000K
YoY Change -22820.0% -8425.0% 300.0%
Pretax Income -$12.51M -$15.10M -$14.83M
YoY Change 88.3% 173.86% 252.25%
Income Tax
% Of Pretax Income
Net Earnings -$12.51M -$15.10M -$14.83M
YoY Change 88.3% 173.86% 252.25%
Net Earnings / Revenue
Basic Earnings Per Share -$0.30 -$0.36 -$0.36
Diluted Earnings Per Share -$0.30 -$0.36 -$356.8K
COMMON SHARES
Basic Shares Outstanding 41.97M 41.78M 41.60M
Diluted Shares Outstanding 42.00M 41.78M 41.55M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $263.2M $275.1M $292.5M
YoY Change -15.86% 103.48% 107.98%
Cash & Equivalents $263.2M $275.1M $292.5M
Short-Term Investments
Other Short-Term Assets $4.260M $2.192M $1.526M
YoY Change 528.32% 910.14% 703.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $267.5M $277.3M $294.0M
YoY Change -14.68% 104.77% 108.78%
LONG-TERM ASSETS
Property, Plant & Equipment $1.146M $1.201M $1.008M
YoY Change 47.11% -37.55% 115.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.872M $5.082M $362.0K
YoY Change 1117.61% 97.44% -29.57%
Total Long-Term Assets $8.514M $9.819M $4.946M
YoY Change 244.84% 118.35% 404.18%
TOTAL ASSETS
Total Short-Term Assets $267.5M $277.3M $294.0M
Total Long-Term Assets $8.514M $9.819M $4.946M
Total Assets $276.0M $287.1M $299.0M
YoY Change -12.65% 105.2% 110.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.747M $2.343M $1.356M
YoY Change 32.83% 24.96% 61.24%
Accrued Expenses $2.742M $3.112M $3.545M
YoY Change 1.56% 66.06% 410.81%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.489M $5.455M $4.901M
YoY Change 15.12% 45.51% 219.28%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $226.0K $261.0K $303.0K
YoY Change -47.93% -83.29% -41.95%
Total Long-Term Liabilities $226.0K $261.0K $303.0K
YoY Change -47.93% -83.29% -41.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.489M $5.455M $4.901M
Total Long-Term Liabilities $226.0K $261.0K $303.0K
Total Liabilities $8.229M $8.265M $7.787M
YoY Change 31.9% 55.62% 278.56%
SHAREHOLDERS EQUITY
Retained Earnings -$82.80M -$70.29M -$55.20M
YoY Change 172.0%
Common Stock $350.6M $349.1M $346.4M
YoY Change 3.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $267.8M $278.9M $291.2M
YoY Change
Total Liabilities & Shareholders Equity $276.0M $287.1M $299.0M
YoY Change -12.65% 105.2% 110.83%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$12.51M -$15.10M -$14.83M
YoY Change 88.3% 173.86% 252.25%
Depreciation, Depletion And Amortization $82.00M $69.00M $64.00K
YoY Change 100.0% 165.38% 190.91%
Cash From Operating Activities -$12.21M -$17.17M -$8.925M
YoY Change 118.93% 293.04% 90.79%
INVESTING ACTIVITIES
Capital Expenditures -$48.00K -$251.0K $239.0K
YoY Change -81.25% 4.58% 298.33%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$48.00K -$251.0K -$239.0K
YoY Change -80.0% 4.58% 298.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 364.0K 27.00K 238.0K
YoY Change -99.8% -103.27% -99.82%
NET CHANGE
Cash From Operating Activities -12.21M -17.17M -8.925M
Cash From Investing Activities -48.00K -251.0K -239.0K
Cash From Financing Activities 364.0K 27.00K 238.0K
Net Change In Cash -11.90M -17.39M -8.926M
YoY Change -106.7% 220.06% -107.12%
FREE CASH FLOW
Cash From Operating Activities -$12.21M -$17.17M -$8.925M
Capital Expenditures -$48.00K -$251.0K $239.0K
Free Cash Flow -$12.16M -$16.92M -$9.164M
YoY Change 128.56% 309.81% 93.41%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001863127
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40800
dei Entity Registrant Name
EntityRegistrantName
TYRA BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1476348
dei Entity Address Address Line1
EntityAddressAddressLine1
2656 State Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92008
dei City Area Code
CityAreaCode
619
dei Local Phone Number
LocalPhoneNumber
728-4760
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
TYRA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41973623
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275107000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
302182000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2192000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1875000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
277299000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
304057000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
261000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
367000
CY2022Q2 us-gaap Liabilities
Liabilities
8265000
CY2021Q4 us-gaap Liabilities
Liabilities
4964000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 tyra Right Of Use Asset
RightOfUseAsset
2536000
CY2021Q4 tyra Right Of Use Asset
RightOfUseAsset
1062000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1000000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
243000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1201000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1027000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
15000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3616000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2549000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
981000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5082000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
312000
CY2022Q2 us-gaap Assets
Assets
287118000
CY2021Q4 us-gaap Assets
Assets
306701000
CY2022Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
67000
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
47000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2343000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
599000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
123000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
202000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2989000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2815000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5455000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42580381
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42536183
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41903110
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41441135
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
349141000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
342104000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-70292000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-40371000
tyra Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
6000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
278853000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301737000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287118000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
306701000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12047000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4381000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
118000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21692000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7902000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15095000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5512000
us-gaap Net Income Loss
NetIncomeLoss
-29921000
CY2022Q2 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
186000
CY2021Q2 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
118000
us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
396000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3381000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1127000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8570000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1816000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
15428000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
5508000
us-gaap Operating Expenses
OperatingExpenses
30262000
us-gaap Operating Expenses
OperatingExpenses
9718000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-15428000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5508000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30262000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9718000
CY2022Q2 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
346000
CY2021Q2 tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
4000
tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
364000
tyra Investment Income Interest Expense
InvestmentIncomeInterestExpense
5000
CY2022Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
13000
CY2021Q2 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
23000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
333000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
341000
us-gaap Net Income Loss
NetIncomeLoss
-9721000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.43
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.54
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41777206
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41777206
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2267113
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2267113
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41665155
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41665155
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2139889
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
119980000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2139889
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-13638000
CY2021Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
86000
CY2021Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
65000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-17522000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-5083000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
156000
tyra Share Based Compensation Expense Recognized Over The Requisite Service Period
ShareBasedCompensationExpenseRecognizedOverTheRequisiteServicePeriod
900000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2102000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
171000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
174000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4209000
CY2021Q2 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
1000
CY2021Q2 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
28000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
338000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5512000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-22667000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
301737000
CY2022Q1 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
238000
CY2022Q1 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
63000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3972000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-14826000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
291184000
CY2022Q2 tyra Issuance Of Common Stock Under Benefit Plans
IssuanceOfCommonStockUnderBenefitPlans
34000
CY2022Q2 tyra Vesting Of Shares Of Common Stock Subject To Repurchase
VestingOfSharesOfCommonStockSubjectToRepurchase
42000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2688000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15095000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
278853000
us-gaap Net Income Loss
NetIncomeLoss
-29921000
us-gaap Net Income Loss
NetIncomeLoss
-9721000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
132000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
49000
us-gaap Share Based Compensation
ShareBasedCompensation
6660000
us-gaap Share Based Compensation
ShareBasedCompensation
512000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-2000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26093000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9139000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
490000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
300000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-490000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-300000
tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
265000
tyra Proceeds From Issuance Of Common Stock Under Benefit Plans
ProceedsFromIssuanceOfCommonStockUnderBenefitPlans
536000
tyra Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
0
tyra Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
731000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
265000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
129419000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26318000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
302425000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15467000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135447000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275107000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
276107000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135204000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1000000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
243000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
276107000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135447000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1556000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1215000
tyra Repurchase Of Early Exercise Liability In Accounts Payable
RepurchaseOfEarlyExerciseLiabilityInAccountsPayable
0
tyra Repurchase Of Early Exercise Liability In Accounts Payable
RepurchaseOfEarlyExerciseLiabilityInAccountsPayable
25000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
126000
tyra Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
0
tyra Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
1579000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-02
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0000025974
CY2021Q3 tyra Increase In Authorized Share Due To Forward Stock Split
IncreaseInAuthorizedShareDueToForwardStockSplit
50000000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11748000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1184526
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4154000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4505258
CY2022Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1500000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1196000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
299000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
169000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1201000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1027000
CY2022Q2 us-gaap Depreciation
Depreciation
69000000
us-gaap Depreciation
Depreciation
132000000
CY2021Q2 us-gaap Depreciation
Depreciation
26000000
us-gaap Depreciation
Depreciation
49000000
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4505258
CY2022Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1215000
CY2021Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1278000
CY2022Q2 tyra Accrued Research And Development
AccruedResearchAndDevelopment
1390000
CY2021Q4 tyra Accrued Research And Development
AccruedResearchAndDevelopment
1257000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
156000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
61000
CY2022Q2 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
228000
CY2021Q4 tyra Accrued Other General And Administrative Fees
AccruedOtherGeneralAndAdministrativeFees
219000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2989000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2815000
CY2022Q2 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
4505258
CY2021Q4 tyra Common Stock Options Granted And Outstanding
CommonStockOptionsGrantedAndOutstanding
3771516
CY2022Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11043763
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8535790
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3771516
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.18
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
28901000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
866798
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.57
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
16680
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.25
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
116376
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
14.66
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.79
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41665155
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2139889
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2139889
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
11748000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2687000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
338000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6660000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
512000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
21800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2022Q2 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
427041
CY2021Q4 tyra Provision Related To Repurchase Of Early Exercised Options
ProvisionRelatedToRepurchaseOfEarlyExercisedOptions
599878
CY2022Q2 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
300000
CY2021Q4 tyra Liability Related To Repurchase Of Early Exercised Options
LiabilityRelatedToRepurchaseOfEarlyExercisedOptions
400000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-15095000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5512000
us-gaap Net Income Loss
NetIncomeLoss
-29921000
us-gaap Net Income Loss
NetIncomeLoss
-9721000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41777206
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41777206
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2267113
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2267113
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41665155
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.43
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.54
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5182529
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14197361
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
100000
us-gaap Operating Lease Cost
OperatingLeaseCost
200000
us-gaap Operating Lease Cost
OperatingLeaseCost
100000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
147000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
299000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
309000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
317000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
327000
CY2022Q2 tyra Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
2378000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3777000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1105000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2672000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
123000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2549000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y7M6D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0650
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750

Files In Submission

Name View Source Status
0000950170-22-014802-index-headers.html Edgar Link pending
0000950170-22-014802-index.html Edgar Link pending
0000950170-22-014802.txt Edgar Link pending
0000950170-22-014802-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tyra-20220630.htm Edgar Link pending
tyra-20220630.xsd Edgar Link pending
tyra-20220630_cal.xml Edgar Link unprocessable
tyra-20220630_def.xml Edgar Link unprocessable
tyra-20220630_htm.xml Edgar Link completed
tyra-20220630_lab.xml Edgar Link unprocessable
tyra-20220630_pre.xml Edgar Link unprocessable
tyra-ex10_1.htm Edgar Link pending
tyra-ex31_1.htm Edgar Link pending
tyra-ex31_2.htm Edgar Link pending
tyra-ex32_1.htm Edgar Link pending
tyra-ex32_2.htm Edgar Link pending